Aspen Neuroscience, Inc. (ASPE)

Aspen Neuroscience Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Operating Activities

Year Ending	TTM	Dec 31, 2025	Dec 31, 2024
Net Income	-66.84	-62.06	-48.56
Depreciation & Amortization	4.13	3.96	3.51
Share-Based Compensation	-	2.52	2.71
Other Operating Activities	5.98	2.73	-1.83
Operating Cash Flow	-56.73	-52.85	-44.16
Operating Cash Flow Growth	-	-	-

Investing Activities

Year Ending	TTM	Dec 31, 2025	Dec 31, 2024
Capital Expenditures	-9.78	-9.69	-2.58
Change in Investments	-	13.89	23.22
Investing Cash Flow	-46.17	4.2	20.63

Financing Activities

Year Ending	TTM	Dec 31, 2025	Dec 31, 2024
Share Issuance / Repurchase	-	115.53	0.47
Other Financing Activities	114.78	-	-0.01
Financing Cash Flow	114.78	115.53	0.46

Net Cash Flow

Year Ending	TTM	Dec 31, 2025	Dec 31, 2024
Net Cash Flow	11.88	66.88	-23.07

Free Cash Flow

Year Ending	TTM	Dec 31, 2025	Dec 31, 2024
Free Cash Flow	-66.51	-62.54	-46.75
Free Cash Flow Growth	-	-	-

Data Source: SEC filings Last updated: Dec 31, 2025

The financial data was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error